Wegovy HD launches in the United States

Novo Nordisk began selling a new, higher-dose version of Wegovy in the United States in April 2026. The product, called Wegovy HD, delivers 7.2 milligrams of semaglutide through a single-dose pen, one step above the previous top dose of 2.4 mg.^[1] It is now available through all the usual semaglutide channels, including pharmacies and Novo Nordisk's own NovoCare Pharmacy service.^[1][2]

For patients who are new to NovoCare Pharmacy and paying out of pocket, the company's pricing terms show an introductory rate of $199 a month for the lower 0.25 mg and 0.5 mg starter doses, good for two monthly fills through the end of 2026. After that window, self-pay patients move to standard pricing: $349 a month for the 0.25 mg through 2.4 mg doses, and $399 a month specifically for Wegovy HD at 7.2 mg. One month is defined as one box of four pens.^[2] Novo Nordisk says it can change or cancel these offers at any time, and eligibility rules apply.^[2]

The launch of Wegovy HD came alongside broader growth for the company's obesity drugs. In its second-quarter 2026 financial report, Novo Nordisk said its Obesity care unit posted adjusted sales growth of 19% at constant exchange rates, and total weekly Wegovy prescriptions in the US, across pill and injectable forms, reached about 575,000 for the week ending July 17, 2026. Roughly 265,000 of those weekly prescriptions were for the Wegovy pill alone, which has racked up more than 5 million prescriptions since its own launch.^[1]

The higher 7.2 mg dose is also moving beyond the US. Novo Nordisk launched the same single-dose pen in the United Kingdom in June 2026 and plans to roll it out across the European Union in the second half of 2026. In July, the European Medicines Agency approved the 7.2 mg pen based on data from the STEP UP trial program, which the company says showed up to 20.7% mean weight loss.^[1] That figure comes from Novo Nordisk's own regulatory and financial disclosures; independent, peer-reviewed confirmation of the 20.7% figure is not included in these sources.

Why it matters for patients

For people already on Wegovy who feel their current dose isn't producing enough weight loss, the arrival of a 7.2 mg option gives prescribers another dose to consider. But the sources here do not spell out who is a candidate for the higher dose, how it compares head-to-head with the 2.4 mg dose in real-world use, or what side effects look like at this level. Patients considering a change in dose would need that information from their prescriber and the drug's official prescribing information, not from a company earnings report.

Cost is the other practical issue. The $399-a-month self-pay price applies only to the HD dose and only after an initial two-fill introductory period that Novo Nordisk currently caps at $199 a month for lower doses. Patients using insurance, Medicare, or other coverage may pay very different amounts, and the sources here describe self-pay pharmacy pricing, not what any particular insurance plan will charge.^[2] Because Novo Nordisk reserves the right to modify or cancel these offers at any time, the prices reported here reflect terms as described in current company materials rather than a guaranteed long-term rate.^[2]

What happens next

Novo Nordisk has said it plans to expand the 7.2 mg single-dose pen into additional European Union markets in the second half of 2026, following its UK launch in June and EU approval in July.^[1] The company has not detailed, in these sources, any further US pricing changes or a timeline for when the introductory $199 rate for lower Wegovy doses is set to expire beyond the stated December 31, 2026 cutoff.^[2]